This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Stage I-III at initial NSCLC diagnosis
* Aged ≥18 years at first diagnosis of NSCLC
* Timeframe of NSCLC diagnosis:
For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Exclusion Criteria:
* NSCLC is not the primary cancer diagnosis
* Patients with a recent history of other tumor or concurrent other tumor
* Patients participating in interventional clinical trials at time of initial diagnosis
* Patients with positive pregnancy status at the time of diagnosis
Primary outcome measure(s)
Treatment Patterns — Up to 50 months Proportion of patients with different treatment regimens
Proportion of unresected patients in SI/II/III — Up to 50 months Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
CRT rate in USIII — Up to 50 months Proportion of patients who have CRT regimen among unresected SIII patients enrolled
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.